ITCI - Intra-Cellular Therapies, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
11.75
-0.25 (-2.08%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close12.00
Open12.02
Bid11.75 x 3000
Ask15.00 x 800
Day's Range11.71 - 12.26
52 Week Range10.21 - 25.82
Volume214,848
Avg. Volume397,165
Market Cap643.034M
Beta (3Y Monthly)1.98
PE Ratio (TTM)N/A
EPS (TTM)-2.65
Earnings DateAug 3, 2017 - Aug 7, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est29.33
Trade prices are not sourced from all markets
  • Read This Before Buying Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares
    Simply Wall St.12 hours ago

    Read This Before Buying Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The flip side of that is that there are more Read More...

  • ACCESSWIRE21 days ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intra-Cellular Therapies, Inc. - ITCI

    NEW YORK, NY / ACCESSWIRE / January 3, 2019 / Pomerantz LLP is investigating claims on behalf of investors of Intra-Cellular Therapies, Inc. ("Intra-Cellular" or the "Company") (NASDAQ: ITCI) Investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Intra-Cellular and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. On December 18, 2018, Intra-Cellular Therapies issued a press release announcing that "an independent data monitoring committee (DMC) has completed a pre-specified interim analysis of the Company's ongoing clinical trial with low-dose lumateperone (9 mg ITI-007) for the treatment of agitation in patients with probable Alzheimer's disease (Study 201)." Intra-Cellular Therapies stated that "[t]he DMC concluded that Study 201 is not likely to meet its primary endpoint upon completion and therefore recommended the study should be stopped for futility.

  • GlobeNewswire21 days ago

    Intra-Cellular Therapies to Present at the 37th Annual J.P. Morgan Healthcare Conference

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco at the Westin St. Francis Hotel. The live and archived webcast can be accessed under "Press Releases & Events" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease.

  • GlobeNewswire24 days ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intra-Cellular Therapies, Inc. - ITCI

    NEW YORK, Dec. 30, 2018 -- Pomerantz LLP is investigating claims on behalf of investors of Intra-Cellular Therapies, Inc. (“Intra-Cellular” or the “Company”) (NASDAQ: ITCI).

  • ACCESSWIRE27 days ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intra-Cellular Therapies, Inc. - ITCI

    NEW YORK, NY / ACCESSWIRE / December 28, 2018 / Pomerantz LLP is investigating claims on behalf of investors of Intra-Cellular Therapies, Inc. ("Intra-Cellular" or the "Company") (ITCI) Investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Intra-Cellular and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. On December 18, 2018, Intra-Cellular Therapies issued a press release announcing that "an independent data monitoring committee (DMC) has completed a pre-specified interim analysis of the Company's ongoing clinical trial with low-dose lumateperone (9 mg ITI-007) for the treatment of agitation in patients with probable Alzheimer's disease (Study 201)." Intra-Cellular Therapies stated that "[t]he DMC concluded that Study 201 is not likely to meet its primary endpoint upon completion and therefore recommended the study should be stopped for futility.

  • Is Intra-Cellular Therapies Inc (ITCI) A Good Stock To Buy?
    Insider Monkeylast month

    Is Intra-Cellular Therapies Inc (ITCI) A Good Stock To Buy?

    Many investors, including Paul Tudor Jones or Stan Druckenmiller, have been saying for a while now that the current market is overvalued due to a low interest rate environment that leads to companies swapping their equity for debt and focusing mostly on short-term performance such as beating the quarterly earnings estimates. In the fourth quarter, […]

  • PR Newswirelast month

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intra-Cellular Therapies, Inc. - ITCI

    NEW YORK , Dec. 18, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Intra-Cellular Therapies, Inc. ("Intra-Cellular" or the "Company") (NASDAQ: ...

  • GlobeNewswirelast month

    SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Intra-Cellular Therapies, Inc. (ITCI)

    NEW YORK, Dec. 18, 2018 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Intra-Cellular Therapies,.

  • MarketWatchlast month

    Intra-Cellular Therapies stock down 22% after discontinuation of Phase 3 trial

    Shares of Intra-Cellular Therapies Inc. plummeted 22% in pre-market trade Tuesday after the company announced it would discontinue its Phase 3 clinical trial of lumateperone for the treatment of agitation in patients with Alzheimer's disease. An interim analysis of the the trial concluded it would likely not meet its primary endpoint. "Effective clinical study design is a challenge, especially for a therapeutic indication for which there are no approved treatments," said Dr. Sharon Mates, the company's chairman and CEO, in a statement. Shares of Intra-Cellular Therapies have fallen 11.1% in the year to date, while the SPDR S&P Biotech ETF , which includes smaller biotech companies, has fallen 11.6%. The S&P 500 has fallen 4.8%.

  • GlobeNewswirelast month

    Intra-Cellular Therapies Announces Update on ITI-007-201 Clinical Trial for Treatment of Agitation in Patients with Probable Alzheimer's Disease

    “We are disappointed for patients suffering from Alzheimer's disease that the interim analysis did not detect a signal that would warrant continuation of this study. Effective clinical study design is a challenge, especially for a therapeutic indication for which there are no approved treatments," said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies.

  • Simply Wall St.last month

    How Should Investors React To Intra-Cellular Therapies, Inc.’s (NASDAQ:ITCI) CEO Pay?

    Sharon Mates became the CEO of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) in 2013. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar Read More...

  • GlobeNewswirelast month

    Intra-Cellular Therapies Announces Favorable Results From Long-Term Open-Label Safety Switching Study With Lumateperone in Patients with Schizophrenia at the 57th Annual Meeting of the American College of Neuropsychopharmacology

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced favorable results from  the second part  of its open-label safety switching study (Study 303) assessing the effects of long-term administration of lumateperone in patients with stable symptoms of schizophrenia at the 57th Annual Meeting of the American College of Neuropsychopharmacology (ACNP) held in Hollywood, FL, December 9-13, 2018. Poster T184 entitled "Long-Term Safety for Lumateperone (ITI-007) in the Treatment of Schizophrenia" is being presented today from 5:30 pm — 7:30 pm during Poster Session II. The poster presented data demonstrating that lumateperone, administered for up to one year, was generally well tolerated and exhibited statistically significant improvements from baseline on key safety measures of body weight, cardiometabolic and endocrine parameters, without motor side effects often associated with other antipsychotic medications.

  • GlobeNewswirelast month

    Intra-Cellular Therapies Announces FDA Acceptance of New Drug Application for Lumateperone for the Treatment of Schizophrenia

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for lumateperone, an investigational agent for the treatment of schizophrenia. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of September 27, 2019. “The FDA’s acceptance of our NDA submission for lumateperone for the treatment of schizophrenia represents an important milestone and brings us closer to offering a potential advance in the treatment of patients suffering from schizophrenia,” said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of ITCI earnings conference call or presentation 7-Nov-18 1:30pm GMT

    Q3 2018 Intra-Cellular Therapies Inc Earnings Call

  • Simply Wall St.3 months ago

    Does Intra-Cellular Therapies Inc (NASDAQ:ITCI) Have A High Beta?

    If you own shares in Intra-Cellular Therapies Inc (NASDAQ:ITCI) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...

  • Associated Press3 months ago

    Intra-Cellular: 3Q Earnings Snapshot

    On a per-share basis, the New York-based company said it had a loss of 76 cents. The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...

  • GlobeNewswire3 months ago

    Intra-Cellular Therapies to Host Third Quarter 2018 Financial Results Conference Call and Webcast

    NEW YORK, Nov. 01, 2018 -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI) a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS).

  • Intra-Cellular Therapies Sees Hammer Chart Pattern: Time to Buy?
    Zacks3 months ago

    Intra-Cellular Therapies Sees Hammer Chart Pattern: Time to Buy?

    Intra-Cellular Therapies has been struggling lately, but the selling pressure may be coming to an end soon.

  • Options Traders Expect Huge Moves in Intra-Cellular (ITCI) Stock
    Zacks4 months ago

    Options Traders Expect Huge Moves in Intra-Cellular (ITCI) Stock

    Intra-Cellular (ITCI) needs investors to pay close attention to the stock based on moves in the options market lately.